Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease

BACKGROUND Patients with chronic obstructive pulmonary disease (COPD) often present with severe acute exacerbations requiring hospital treatment. However, little is known about the prognostic consequences of these exacerbations. A study was undertaken to investigate whether severe acute exacerbations of COPD exert a direct effect on mortality. METHODS Multivariate techniques were used to analyse the prognostic influence of acute exacerbations of COPD treated in hospital (visits to the emergency service and admissions), patient age, smoking, body mass index, co-morbidity, long term oxygen therapy, forced spirometric parameters, and arterial blood gas tensions in a prospective cohort of 304 men with COPD followed up for 5 years. The mean (SD) age of the patients was 71 (9) years and forced expiratory volume in 1 second was 46 (17)%. RESULTS Only older age (hazard ratio (HR) 5.28, 95% CI 1.75 to 15.93), arterial carbon dioxide tension (HR 1.07, 95% CI 1.02 to 1.12), and acute exacerbations of COPD were found to be independent indicators of a poor prognosis. The patients with the greatest mortality risk were those with three or more acute COPD exacerbations (HR 4.13, 95% CI 1.80 to 9.41). CONCLUSIONS This study shows for the first time that severe acute exacerbations of COPD have an independent negative impact on patient prognosis. Mortality increases with the frequency of severe exacerbations, particularly if these require admission to hospital.

[1]  Grupo de Trabajo de la Separ,et al.  Normativa para la práctica de la espirometría forzada , 1989 .

[2]  W. Knaus,et al.  Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. , 1996, JAMA.

[3]  V. Brusasco,et al.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.

[4]  W. Bailey,et al.  Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. , 2000, American journal of respiratory and critical care medicine.

[5]  N. Pride,et al.  Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice , 2002, European Respiratory Journal.

[6]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[7]  J. Wedzicha,et al.  Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[8]  L Goldman,et al.  Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) , 1996, American journal of respiratory and critical care medicine.

[9]  Alan D. Lopez,et al.  Mortality by cause for eight regions of the world: Global Burden of Disease Study , 1997, The Lancet.

[10]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[11]  Toru Oga,et al.  Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. , 2002, Chest.

[12]  C. Jenkins,et al.  The TORCH (TOwards a Revolution in COPD Health) survival study protocol , 2004, European Respiratory Journal.

[13]  M. Martínez-García,et al.  Mid-arm muscle area is a better predictor of mortality than body mass index in COPD. , 2006, Chest.

[14]  Emiel F M Wouters,et al.  Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. , 2003, Chest.

[15]  D.,et al.  Regression Models and Life-Tables , 2022 .

[16]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[17]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[18]  N. Anthonisen,et al.  Prognosis in chronic obstructive pulmonary disease. , 1990, The American review of respiratory disease.

[19]  A. Chaouat,et al.  Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. , 1995, Chest.

[20]  T. Seemungal,et al.  Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations , 2002, Thorax.

[21]  J. Vestbo,et al.  Prognostic value of nutritional status in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[22]  D. Navajas,et al.  Spirometric reference values from a Mediterranean population. , 1986, Bulletin europeen de physiopathologie respiratoire.

[23]  M. Malesker,et al.  Pharmacoeconomic evaluation of COPD. , 2000, Chest.

[24]  R. Rodríguez-Roisín,et al.  Toward a consensus definition for COPD exacerbations. , 2000, Chest.

[25]  S. Quintana,et al.  Mortality after hospitalization for COPD. , 2002, Chest.

[26]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[27]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[28]  Jordi Alonso,et al.  Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[29]  B. Burrows,et al.  Prediction of survival in patients with chronic airway obstruction. , 1969, The American review of respiratory disease.

[30]  M. Artés,et al.  Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitación Obstructiva al Flujo aEreo. , 1999, Respiratory medicine.

[31]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[32]  M. Tsukino,et al.  Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. , 2003, American journal of respiratory and critical care medicine.

[33]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[34]  R. Pistelli,et al.  Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. , 1995, The American journal of medicine.

[35]  F. Forastiere,et al.  Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. , 1997, The European respiratory journal.

[36]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[37]  T. Seemungal,et al.  Longitudinal changes in the nature, severity and frequency of COPD exacerbations , 2003, European Respiratory Journal.

[38]  N. Anthonisen,et al.  Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. , 2001, American journal of respiratory and critical care medicine.

[39]  L. Tanoue,et al.  Erlotinib in Previously Treated Non-Small-Cell Lung Cancer , 2007 .

[40]  M. Perpiñá,et al.  Impacto asistencial hospitalario de la EPOC. Peso específico del paciente con EPOC de alto consumo sanitario , 2001 .